Gary Bohnert, Ph.D.

Gary Bohnert, Ph.D. brings more than 18 years of experience in medicinal chemistry, drug discovery, and project leadership to his role at Cognesy.

Previously, Dr. Bohnert served as principal investigator at EMD Serono where he initiated and managed multiple HTS and phenotypic screening programs. He also served as an Investigator at Tempero Pharmaceuticals and later at GlaxoSmithKline, where his teams progressed molecules from hit through lead optimization, including a Th17-modulating development candidate. Dr. Bohnert began his career in the medicinal chemistry group at Synta Pharmaceuticals, where he used ligand-based drug design for ion channel modulation as with the invention of RO2959.

Dr. Bohnert received a Ph.D. in organic chemistry from the University of Missouri-Columbia and a B.S. in chemistry from Southeast Missouri University. He completed his postdoctoral training at Boston University, and has more than 22 scientific patents and publications.